BBIO BridgeBio Pharma, Inc.

78.18USD+0.22%Mkt Cap: 15.23B USDP/E: —

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR sta…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap15.23B USD
Enterprise Value17.99B USD
Revenue (TTM)945.54M USD
Gross Profit481.11M USD
Net Income (TTM)-724.93M USD
Revenue/Share4.85 USD
Last Price78.18 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.1K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-286.02
PEG—
EV/EBITDA-51.63
EV/Revenue19.02
P/S16.11
P/B-5.88
EPS (TTM)-3.03 USD
EPS (Forward)-0.27 USD
52W Range
60.5554% of range93.42
52W High93.42 USD
52W Low60.55 USD
Profitability
Gross Margin95.82%
Oper. Margin-37.34%
EBITDA Margin-36.84%
Profit Margin-144.39%
ROE34.74%
ROA-77.45%
ROIC—
ROCE-77.47%
Growth
Revenue Growth192.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-445.91M USD
CapEx (TTM)9.59M USD
FCF Margin-30.37%
FCF Yield-1.89%
Net Debt1.84B USD
Net Debt/EBITDA-5.28
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.89
Current Ratio2.09
Quick Ratio1.96
Book Value/Sh-13.29 USD
Cash/Share7.90 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)107.00 USD
Upside (mean)+36.9%
Target Range80.00 USD – 156.00 USD
80.00+36.9% to mean156.00
# Analysts20
Ownership
Shares Out.194.80M
Float163.00M
Insiders3.93%
Institutions101.43%
Short Interest
Short Ratio7.3d
Short % Float11.95%
Short % Out.10.70%
Shares Short20.85M
Short (prev mo.)19.67M
Technical
SMA 5070.03 (+11.6%)
SMA 20072.69 (+7.5%)
Beta0.94
S&P 52W Chg12.08%
Avg Vol (30d)2.79M
Avg Vol (10d)2.75M
Technical Indicators
RSI (14)62.5
MACD2.2907
MACD Signal2.1692
MACD Hist.+0.1215
BB Upper82.42 USD
BB Middle75.05 USD
BB Lower67.69 USD
BB Width19.63%
ATR (14)2.586 USD
Vol Ratio (20d)0.72x

About BridgeBio Pharma (NASDAQ: BBIO)

›

BridgeBio Pharma (NASDAQ: BBIO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,081 employees.

The shares were at 78.18 USD on 19 November 2026, up 24.6% over 52 weeks. Its 52-week range is 60.55 USD to 93.42 USD: the price is 16.3% below the high and 29.1% above the low.

Its market capitalisation is 15.23B USD.

BridgeBio Pharma reports return on equity of 34.7%, an operating margin of -37.3% and revenue up 192.6% year over year.

Its debt exceeds its cash by 1.84B USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 20 analysts cover the stock, with an average rating of Buy; their mean price target of 107.00 USD is 36.9% above the current price. The next earnings report is expected on 23 February 2027.